Two bioactive compounds from Tinospora cordifolia — PubChem IDs 137706608 and 5281712 — emerged as top candidates from a virtual screen of 175 plant-derived molecules evaluated against the Smoothened (Smo) receptor of the sonic hedgehog (SHH) signaling pathway. Using integrated in silico methods including molecular docking, MM-GBSA binding affinity estimation, ADMET profiling, and molecular dynamics simulation, both compounds demonstrated CNS penetrance, blood-brain barrier permeability, zero Lipinski violations, and no P-glycoprotein efflux liability — a pharmacokinetic profile that synthetic Smo agonists like purmorphamine often struggle to match.
The significance here lies in the therapeutic bottleneck these compounds could help unlock. Remyelination failure in multiple sclerosis stems largely from oligodendrocyte progenitor cells' (OPCs) inability to mature into functional myelinating oligodendrocytes — a process SHH/Smo signaling actively drives. Existing protocols for OPC induction from stem cells remain dependent on artificial agonists with toxicity or delivery concerns. Identifying plant-derived alternatives with favorable CNS pharmacokinetics is genuinely useful, situating this work at the intersection of computational drug discovery and neuroregeneration.
However, this is entirely computational. No in vitro or in vivo validation exists yet — a limitation the authors forthrightly acknowledge. Binding affinity in silico does not guarantee receptor activation, and Gli reporter assays, OPC differentiation markers, and myelin gene expression studies remain essential next steps. For now, this is a well-structured lead-identification study — incremental but directionally promising for MS neuroregenerative drug discovery.